Reducing the Gastrointestinal Risks of Low-Dose Aspirin

Gastroenterology

Volumn 138, Issue 1, 2010, Pages 30-33

  Cryer, Byron ^a  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FAMOTIDINE; PANTOPRAZOLE;

DIGESTIVE SYSTEM INJURY; DIGESTIVE SYSTEM ULCER; EDITORIAL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HOMEOSTASIS; HUMAN; LOW DRUG DOSE; PRIORITY JOURNAL; RISK FACTOR; STOMACH DISEASE;

EID: 72249105523     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.11.032     Document Type: Editorial

References (24)

1. Mahe I., Leizorovicz A., Caulin C., et al. Aspirin for the prevention of cardiovascular events in the elderly. Drugs Aging 20 (2003) 999-1010
2. Ajani U.A., Ford E.S., Greenland K.J., et al. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med 30 (2006) 74-77
3. Bhatt D.L., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 103 (2008) 2890-2907
4. Weil J., Colin-Jones D., Langman M., et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310 (1995) 827-830
5. McQuaid K., and Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 119 (2006) 624-638
6. Cryer B., and Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117 (1999) 17-25
7. Hernandez-Diaz S., and Garcia Rodriguez L.A. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 4 (2006) 22
8. Lai K.C., Lam S.K., Chu K.M., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 (2002) 2033-2038
9. Cryer B. Mucosal defense and repair. Role of prostaglandins in the stomach and duodenum. Gastroenterol Clin North Am 30 (2001) 877-894
10. Davenport H.W. Damage to the gastric mucosa: effects of salicylates and stimulation. Gastroenterology 49 (1965) 189-196
11. Lichtenberger L.M., Zhou Y., Dial E.J., et al. NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. J Pharm Pharmacol 58 (2006) 1421-1428
12. Chan F.K.L., Chung S.C., Yuen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344 (2001) 967-973
13. Yeomans N., Lanas A., Labenz J., et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 103 (2008) 2465-2473
14. Taha A.S., McCloskey C., Prasad R., et al. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet 374 (2009) 119-125
15. Richter J.E. Gastroesophageal reflux disease and its complications. In: Feldman M., et al. (Ed). Sleisenger and Fordtran's gastrointestinal and liver disease. 8th ed. (2006), Saunders Elsevier, Philadelphia 905-936 Vol. 1
16. Graham D.Y., Agrawal N.M., Campbell D.R., et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs. lansoprazole. Arch Intern Med 162 (2002) 169-175
17. Scheiman J.M., Yeomans N.D., Talley N.J., et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101 (2006) 701-710
18. Yeomans N.D., Tulassay Z., Juhasz L., et al. Omeprazole compared with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 338 (1998) 719-726
19. Ng FH., Wong SY., Lam KF., et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 138 (2010) 82-88
20. Graham D.Y. Endoscopic ulcers are neither meaningful nor validated as a surrogate for clinically significant upper gastrointestinal harm. Clin Gastroenterol Hepatol 7 (2009) 1147-1150
21. Moore A., Bjarnason I., Cryer B., et al. Evidence for endoscopic ulcers as meaningful surrogate endpoint for clinically significant upper gastrointestinal harm. Clin Gastroenterol Hepatol 7 (2009) 1156-1163
22. Tramer M.R., Moore R.A., Reynolds D.J., et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 85 (2000) 169-182
23. Hawkey C.J. Non-steroidal anti-inflammatory drugs and peptic ulcers. BMJ 300 (1990) 278-284
24. Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol 102 (2007) 507-515